Moffitt Cancer Center subsidiary M2Gen has joined Deloitte’s analytics consortium to help provide medicine studies and services to life science organizations and cancer centers.
M2Gen intends to contribute to the ConvergeHEALTH consortium’s works of identifying biomarkers, matching gene-based clinical trial and creating real-world evidence, Deloitte said Tuesday.
Nitin Mittal, principal at Deloitte and executive vice president of services for ConvergeHEALTH, said the partnership aims to help oncology centers engage patients and collaborate with other centers by combining Moffitt’s Total Cancer Care program with research informatics systems and consulting services.
M2Gen works to build a clinical and molecular data repository out of the information and tissue donated by patients under the Total Cancer Care protocol.
The alliance is also formed to conduct personalized medicine studies using ConvergeHEALTH’s OutcomesMiner suite, informatics and consulting services.